Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01243424
First received: November 17, 2010
Last updated: November 5, 2014
Last verified: November 2014
  Purpose

The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: linagliptin
Drug: glimepiride
Drug: linagliptin placebo
Drug: glimepride placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Time to first occurence of any of the following adjudicated components of the primary composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalisation for unstable angina pectoris [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI) [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients on study treatment at study end, that at Final Visit maintain glycemic control (HbA1c <= 7.0%) without need for rescue medication, without any moderate/severe hypoglycaemic episodes and without > 2% weight gain (from V6 on) [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Occurence of any of the adjudicated components of the composite primary and composite first key secondary endpoint. [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Transitions in albuminuria classes between baseline and Final visit. [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients on study treatment at study end, that at Final Visit maintain glycaemic control (HbA1c <= 7.0%) without need for rescue medication and without > 2% weight gain (from V6 on) [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Occurence of and time to composite endpoint of all CEC confirmed adjudicated events [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to Final Visit in diabetes related laboratory parameters: HbA1c, fasting plasma glucose, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides, Creatinine, eGFR (MDRD formula), Albumin [ Time Frame: 400 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 6000
Study Start Date: October 2010
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: linagliptin
patient to receive linagliptin or glimepiride placebo overencapsulated tablet QD
Drug: linagliptin
linagliptin tablets 5mg QD
Drug: glimepride placebo
glimepiride placebo
Active Comparator: glimepiride 1-4 mg QD
patient to receive glimepiride 1-4 mg or linagliptin placebo tablet QD
Drug: glimepiride
glimepiride over-encapsulated tablet 1-4 mg QD
Drug: linagliptin placebo
linagliptin placebo

  Eligibility

Ages Eligible for Study:   40 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Type 2 diabetes
  2. Elevated glycosylated heamoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 - 7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with metformin OR an alpha-glucosidase inhibitor) therapy)
  3. Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age => 70 years OR two or more specified cardiovascular risk factor

Exclusion criteria:

  1. Type 1 diabetes
  2. Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV) inhibitors or any insulin) prior to informed consent (previous short term use of insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)
  3. Inappropriateness of glimepiride treatment for renal safety issues according to local prescribing information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01243424

  Hide Study Locations
Locations
United States, Alabama
1218.74.01113 Boehringer Ingelheim Investigational Site
Athens, Alabama, United States
1218.74.01067 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1218.74.01079 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1218.74.01013 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1218.74.01231 Boehringer Ingelheim Investigational Site
Montgomery, Alabama, United States
1218.74.01029 Boehringer Ingelheim Investigational Site
Muscle Shoals, Alabama, United States
United States, Alaska
1218.74.01072 Boehringer Ingelheim Investigational Site
Little Rock, Alaska, United States
1218.74.01084 Boehringer Ingelheim Investigational Site
Pell City, Alaska, United States
United States, Arizona
1218.74.01182 Boehringer Ingelheim Investigational Site
Mesa, Arizona, United States
1218.74.01200 Boehringer Ingelheim Investigational Site
Mesa, Arizona, United States
1218.74.01047 Boehringer Ingelheim Investigational Site
Tuscon, Arizona, United States
United States, Arkansas
1218.74.01155 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas, United States
1218.74.01204 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
United States, California
1218.74.01108 Boehringer Ingelheim Investigational Site
Bermuda Dunes, California, United States
1218.74.01119 Boehringer Ingelheim Investigational Site
Fountain Valley, California, United States
1218.74.01233 Boehringer Ingelheim Investigational Site
Fullerton, California, United States
1218.74.01209 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
1218.74.01015 Boehringer Ingelheim Investigational Site
Los Gatos, California, United States
1218.74.01144 Boehringer Ingelheim Investigational Site
North Hollywood, California, United States
1218.74.01043 Boehringer Ingelheim Investigational Site
Pomona, California, United States
1218.74.01094 Boehringer Ingelheim Investigational Site
Redondo Beach, California, United States
1218.74.01227 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1218.74.01160 Boehringer Ingelheim Investigational Site
San Ramon, California, United States
1218.74.01125 Boehringer Ingelheim Investigational Site
Sylmar, California, United States
1218.74.01028 Boehringer Ingelheim Investigational Site
Tarzana, California, United States
1218.74.01068 Boehringer Ingelheim Investigational Site
Tustin, California, United States
1218.74.01090 Boehringer Ingelheim Investigational Site
Tustin, California, United States
1218.74.01069 Boehringer Ingelheim Investigational Site
Westlake Village, California, United States
United States, Colorado
1218.74.01222 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1218.74.01240 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
United States, Florida
1218.74.01138 Boehringer Ingelheim Investigational Site
Boca Raton, Florida, United States
1218.74.01156 Boehringer Ingelheim Investigational Site
Davie, Florida, United States
1218.74.01212 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida, United States
1218.74.01117 Boehringer Ingelheim Investigational Site
Doral, Florida, United States
1218.74.01197 Boehringer Ingelheim Investigational Site
Edgewater, Florida, United States
1218.74.01026 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
1218.74.01121 Boehringer Ingelheim Investigational Site
Ft. Lauderdale, Florida, United States
1218.74.01127 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1218.74.01151 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1218.74.01174 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1218.74.01188 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1218.74.01165 Boehringer Ingelheim Investigational Site
Lauderdale Lakes, Florida, United States
1218.74.01194 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01226 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01016 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01056 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01089 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01091 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01191 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01070 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.74.01193 Boehringer Ingelheim Investigational Site
Miami Lakes, Florida, United States
1218.74.01002 Boehringer Ingelheim Investigational Site
New Port Richey, Florida, United States
1218.74.01017 Boehringer Ingelheim Investigational Site
New Port Richey, Florida, United States
1218.74.01230 Boehringer Ingelheim Investigational Site
Opa Locka, Florida, United States
1218.74.01085 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1218.74.01104 Boehringer Ingelheim Investigational Site
Palm Harbor, Florida, United States
1218.74.01095 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
1218.74.01124 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1218.74.01195 Boehringer Ingelheim Investigational Site
Ponte Vedra, Florida, United States
1218.74.01164 Boehringer Ingelheim Investigational Site
South Miami, Florida, United States
1218.74.01065 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida, United States
United States, Georgia
1218.74.01205 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1218.74.01172 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1218.74.01149 Boehringer Ingelheim Investigational Site
Dunwoody, Georgia, United States
1218.74.01208 Boehringer Ingelheim Investigational Site
Snellville, Georgia, United States
United States, Idaho
1218.74.01141 Boehringer Ingelheim Investigational Site
Hayden Lake, Idaho, United States
1218.74.01071 Boehringer Ingelheim Investigational Site
Meridian, Idaho, United States
United States, Illinois
1218.74.01115 Boehringer Ingelheim Investigational Site
Bolingbrook, Illinois, United States
1218.74.01214 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1218.74.01126 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1218.74.01063 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1218.74.01185 Boehringer Ingelheim Investigational Site
Evergreen Park, Illinois, United States
United States, Indiana
1218.74.01007 Boehringer Ingelheim Investigational Site
Avon, Indiana, United States
1218.74.01183 Boehringer Ingelheim Investigational Site
Brownsburg, Indiana, United States
1218.74.01092 Boehringer Ingelheim Investigational Site
Franklin, Indiana, United States
1218.74.01014 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1218.74.01096 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1218.74.01074 Boehringer Ingelheim Investigational Site
Mishawaka, Indiana, United States
1218.74.01018 Boehringer Ingelheim Investigational Site
Munci, Indiana, United States
United States, Kentucky
1218.74.01087 Boehringer Ingelheim Investigational Site
Florence, Kentucky, United States
1218.74.01232 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
1218.74.01218 Boehringer Ingelheim Investigational Site
Madisonville, Kentucky, United States
United States, Louisiana
1218.74.01220 Boehringer Ingelheim Investigational Site
Metairie, Louisiana, United States
United States, Maine
1218.74.01170 Boehringer Ingelheim Investigational Site
Bangor, Maine, United States
United States, Maryland
1218.74.01162 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1218.74.01045 Boehringer Ingelheim Investigational Site
Rockville, Maryland, United States
United States, Massachusetts
1218.74.01122 Boehringer Ingelheim Investigational Site
North Attleboro, Massachusetts, United States
United States, Michigan
1218.74.01166 Boehringer Ingelheim Investigational Site
Canton, Michigan, United States
1218.74.01180 Boehringer Ingelheim Investigational Site
Flint, Michigan, United States
1218.74.01098 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan, United States
1218.74.01025 Boehringer Ingelheim Investigational Site
Livonia, Michigan, United States
1218.74.01035 Boehringer Ingelheim Investigational Site
St. Clair Shores, Michigan, United States
1218.74.01078 Boehringer Ingelheim Investigational Site
Sterling Heights, Michigan, United States
1218.74.01184 Boehringer Ingelheim Investigational Site
Traverse City, Michigan, United States
1218.74.01080 Boehringer Ingelheim Investigational Site
Troy, Michigan, United States
United States, Minnesota
1218.74.01008 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
United States, Mississippi
1218.74.01139 Boehringer Ingelheim Investigational Site
Biloxi, Mississippi, United States
United States, Missouri
1218.74.01049 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Nebraska
1218.74.01060 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, Nevada
1218.74.01187 Boehringer Ingelheim Investigational Site
Henderson, Nevada, United States
1218.74.01133 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
1218.74.01201 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
United States, New Jersey
1218.74.01129 Boehringer Ingelheim Investigational Site
Atco, New Jersey, United States
1218.74.01022 Boehringer Ingelheim Investigational Site
Clifton, New Jersey, United States
1218.74.01118 Boehringer Ingelheim Investigational Site
Elizabeth, New Jersey, United States
United States, New York
1218.74.01229 Boehringer Ingelheim Investigational Site
Albany, New York, United States
1218.74.01048 Boehringer Ingelheim Investigational Site
Smithtown, New York, United States
1218.74.01050 Boehringer Ingelheim Investigational Site
West Seneca, New York, United States
United States, North Carolina
1218.74.01132 Boehringer Ingelheim Investigational Site
Asheville, North Carolina, United States
1218.74.01051 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
1218.74.01103 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1218.74.01134 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1218.74.01021 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
1218.74.01186 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
1218.74.01169 Boehringer Ingelheim Investigational Site
Elizabeth City, North Carolina, United States
1218.74.01238 Boehringer Ingelheim Investigational Site
Raleigh, North Carolina, United States
1218.74.01033 Boehringer Ingelheim Investigational Site
Shelby, North Carolina, United States
1218.74.01041 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
1218.74.01199 Boehringer Ingelheim Investigational Site
Wilmington, North Carolina, United States
United States, Ohio
1218.74.01210 Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
1218.74.01120 Boehringer Ingelheim Investigational Site
Austintown, Ohio, United States
1218.74.01145 Boehringer Ingelheim Investigational Site
Cadiz, Ohio, United States
1218.74.01109 Boehringer Ingelheim Investigational Site
Carlisle, Ohio, United States
1218.74.01097 Boehringer Ingelheim Investigational Site
Genoa, Ohio, United States
1218.74.01053 Boehringer Ingelheim Investigational Site
Marion, Ohio, United States
1218.74.01005 Boehringer Ingelheim Investigational Site
Marion, Ohio, United States
1218.74.01075 Boehringer Ingelheim Investigational Site
Maumee, Ohio, United States
1218.74.01148 Boehringer Ingelheim Investigational Site
Zanesville, Ohio, United States
United States, Oklahoma
1218.74.01175 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
1218.74.01040 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
United States, Oregon
1218.74.01161 Boehringer Ingelheim Investigational Site
Eugene, Oregon, United States
United States, Pennsylvania
1218.74.01150 Boehringer Ingelheim Investigational Site
Harleysville, Pennsylvania, United States
1218.74.01059 Boehringer Ingelheim Investigational Site
Lansdale, Pennsylvania, United States
1218.74.01128 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1218.74.01054 Boehringer Ingelheim Investigational Site
Warminster, Pennsylvania, United States
United States, Rhode Island
1218.74.01038 Boehringer Ingelheim Investigational Site
Cranston, Rhode Island, United States
United States, South Carolina
1218.74.01110 Boehringer Ingelheim Investigational Site
Anderson, South Carolina, United States
1218.74.01237 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1218.74.01052 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1218.74.01236 Boehringer Ingelheim Investigational Site
Orangeburg, South Carolina, United States
1218.74.01215 Boehringer Ingelheim Investigational Site
Sumter, South Carolina, United States
United States, Tennessee
1218.74.01158 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
1218.74.01030 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1218.74.01082 Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
1218.74.01224 Boehringer Ingelheim Investigational Site
Tullahoma, Tennessee, United States
United States, Texas
1218.74.01173 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1218.74.01105 Boehringer Ingelheim Investigational Site
Carrollton, Texas, United States
1218.74.01044 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.74.01046 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.74.01171 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.74.01178 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.74.01006 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.74.01076 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.74.01114 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.74.01167 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.74.01176 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.74.01146 Boehringer Ingelheim Investigational Site
Midland, Texas, United States
1218.74.01031 Boehringer Ingelheim Investigational Site
New Braunfels, Texas, United States
1218.74.01042 Boehringer Ingelheim Investigational Site
Odessa, Texas, United States
1218.74.01179 Boehringer Ingelheim Investigational Site
Pearland, Texas, United States
1218.74.01235 Boehringer Ingelheim Investigational Site
Plano, Texas, United States
1218.74.01088 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1218.74.01112 Boehringer Ingelheim Investigational Site
Schertz, Texas, United States
1218.74.01010 Boehringer Ingelheim Investigational Site
Sugar Land, Texas, United States
United States, Utah
1218.74.01196 Boehringer Ingelheim Investigational Site
Midvale, Utah, United States
1218.74.01140 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah, United States
United States, Virginia
1218.74.01100 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
1218.74.01123 Boehringer Ingelheim Investigational Site
Ettrick, Virginia, United States
1218.74.01239 Boehringer Ingelheim Investigational Site
Henrico, Virginia, United States
1218.74.01003 Boehringer Ingelheim Investigational Site
Manassas, Virginia, United States
1218.74.01228 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
United States, Washington
1218.74.01099 Boehringer Ingelheim Investigational Site
Federal Way, Washington, United States
1218.74.01101 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
Argentina
1218.74.54020 Boehringer Ingelheim Investigational Site
Bahía Blanca, Argentina
1218.74.54007 Boehringer Ingelheim Investigational Site
Caba, Argentina
1218.74.54008 Boehringer Ingelheim Investigational Site
Caba, Argentina
1218.74.54004 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.74.54010 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.74.54018 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.74.54019 Boehringer Ingelheim Investigational Site
Corrientes, Argentina
1218.74.54006 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1218.74.54012 Boehringer Ingelheim Investigational Site
La Plata, Argentina
1218.74.54017 25 de Mayo 1744
Mendoza, Argentina
1218.74.54005 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.74.54009 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.74.54002 Boehringer Ingelheim Investigational Site
Salta, Argentina
1218.74.54013 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán, Argentina
1218.74.54003 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
1218.74.54001 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
Australia, Queensland
1218.74.61002 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
1218.74.61001 Boehringer Ingelheim Investigational Site
Meadowbrook, Queensland, Australia
Australia, South Australia
1218.74.61004 Boehringer Ingelheim Investigational Site
Adelaide, South Australia, Australia
Australia, Victoria
1218.74.61005 Boehringer Ingelheim Investigational Site
East Ringwood, Victoria, Australia
1218.74.61003 Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
Belgium
1218.74.32028 Boehringer Ingelheim Investigational Site
Blankenberge, Belgium
1218.74.32010 Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
1218.74.32003 Boehringer Ingelheim Investigational Site
De Pinte, Belgium
1218.74.32015 Boehringer Ingelheim Investigational Site
Deurne, Belgium
1218.74.32016 Boehringer Ingelheim Investigational Site
Deurne, Belgium
1218.74.32002 Boehringer Ingelheim Investigational Site
Genk, Belgium
1218.74.32025 Boehringer Ingelheim Investigational Site
Gozée, Belgium
1218.74.32009 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
1218.74.32001 Boehringer Ingelheim Investigational Site
Herent, Belgium
1218.74.32024 Boehringer Ingelheim Investigational Site
Linkebeek, Belgium
1218.74.32007 Boehringer Ingelheim Investigational Site
Moorsel, Belgium
1218.74.32004 Boehringer Ingelheim Investigational Site
Natoye, Belgium
1218.74.32027 Boehringer Ingelheim Investigational Site
Retie, Belgium
1218.74.32026 Boehringer Ingelheim Investigational Site
Tremelo, Belgium
Brazil
1218.74.55004 Boehringer Ingelheim Investigational Site
Belém, Brazil
1218.74.55012 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1218.74.55007 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
1218.74.55003 Boehringer Ingelheim Investigational Site
Higienópolis, Brazil
1218.74.55002 Boehringer Ingelheim Investigational Site
Joaquim Távora, Brazil
1218.74.55005 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.74.55006 Boehringer Ingelheim Investigational Site
Río de Janeiro, Brazil
1218.74.55011 Boehringer Ingelheim Investigational Site
Santa Cecília, Brazil
1218.74.55001 Boehringer Ingelheim Investigational Site
São José do Rio Preto, Brazil
1218.74.55010 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.74.55009 Boehringer Ingelheim Investigational Site
Vila Clementino, Brazil
Bulgaria
1218.74.35903 Boehringer Ingelheim Investigational Site
Pleven, Bulgaria
1218.74.35902 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.74.35904 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.74.35905 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.74.35901 Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
Canada, Newfoundland and Labrador
1218.74.02006 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
1218.74.02008 Boehringer Ingelheim Investigational Site
St. John's, Newfoundland and Labrador, Canada
Canada, Ontario
1218.74.02012 Boehringer Ingelheim Investigational Site
Cambridge, Ontario, Canada
1218.74.02011 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1218.74.02004 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1218.74.02009 Boehringer Ingelheim Investigational Site
Thornhill, Ontario, Canada
1218.74.02002 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1218.74.02005 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
Canada, Prince Edward Island
1218.74.02003 Boehringer Ingelheim Investigational Site
Montague, Prince Edward Island, Canada
Canada, Quebec
1218.74.02001 Boehringer Ingelheim Investigational Site
Point Claire, Quebec, Canada
Canada
1218.74.02010 Boehringer Ingelheim Investigational Site
Quebec, Canada
Chile
1218.74.56001 Boehringer Ingelheim Investigational Site
Providencia, Chile
1218.74.56004 Boehringer Ingelheim Investigational Site
Providencia, Chile
1218.74.56002 Boehringer Ingelheim Investigational Site
Temuco, Chile
1218.74.56005 Boehringer Ingelheim Investigational Site
Viña del Mar, Chile
Colombia
1218.74.57002 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.74.57005 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.74.57010 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.74.57006 Boehringer Ingelheim Investigational Site
Bogota, Colombia
1218.74.57001 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1218.74.57007 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1218.74.57011 Boehringer Ingelheim Investigational Site
Cartagena, Colombia
1218.74.57012 Boehringer Ingelheim Investigational Site
Cartagena, Colombia
1218.74.57003 Boehringer Ingelheim Investigational Site
El Bosque, Colombia
1218.74.57004 Boehringer Ingelheim Investigational Site
El Bosque, Colombia
1218.74.57013 Boehringer Ingelheim Investigational Site
Tolima, Colombia
Czech Republic
1218.74.42008 Boehringer Ingelheim Investigational Site
Jablonec nad Nisou, Czech Republic
1218.74.42001 Boehringer Ingelheim Investigational Site
Olomouc-Lazce, Czech Republic
1218.74.42006 Boehringer Ingelheim Investigational Site
Ostrava, Czech Republic
1218.74.42005 Boehringer Ingelheim Investigational Site
Plzen, Czech Republic
1218.74.42009 Boehringer Ingelheim Investigational Site
Praha, Czech Republic
1218.74.42003 Boehringer Ingelheim Investigational Site
Praha 8, Czech Republic
1218.74.42004 Boehringer Ingelheim Investigational Site
Prostejov, Czech Republic
1218.74.42007 Boehringer Ingelheim Investigational Site
Strakonice, Czech Republic
Finland
1218.74.35805 Boehringer Ingelheim Investigational Site
Helsinki, Finland
1218.74.35804 Boehringer Ingelheim Investigational Site
Joensuu, Finland
1218.74.35802 Boehringer Ingelheim Investigational Site
Kerava, Finland
1218.74.35807 Boehringer Ingelheim Investigational Site
Kokkola, Finland
1218.74.35801 Boehringer Ingelheim Investigational Site
Kuopio, Finland
1218.74.35803 Boehringer Ingelheim Investigational Site
Oulu, Finland
1218.74.35806 Boehringer Ingelheim Investigational Site
Turku, Finland
France
1218.74.33010 Boehringer Ingelheim Investigational Site
Behren Les Forbach, France
1218.74.33001 Boehringer Ingelheim Investigational Site
Bordeaux, France
1218.74.33035 Boehringer Ingelheim Investigational Site
Bourg des Comptes, France
1218.74.33024 Boehringer Ingelheim Investigational Site
Broglie, France
1218.74.33034 Boehringer Ingelheim Investigational Site
Béziers, France
1218.74.33008 Boehringer Ingelheim Investigational Site
Cannes, France
1218.74.33020 Boehringer Ingelheim Investigational Site
Carbonne, France
1218.74.33021 Boehringer Ingelheim Investigational Site
Castets, France
1218.74.33016 Boehringer Ingelheim Investigational Site
Chartres, France
1218.74.33023 Boehringer Ingelheim Investigational Site
Chartres, France
1218.74.33030 Boehringer Ingelheim Investigational Site
Cournonterral, France
1218.74.33028 Boehringer Ingelheim Investigational Site
Fort de France, France
1218.74.33022 Boehringer Ingelheim Investigational Site
Hinx, France
1218.74.33027 Boehringer Ingelheim Investigational Site
La Reunion, France
1218.74.33029 Boehringer Ingelheim Investigational Site
Labarthe Sur Leze, France
1218.74.33033 Boehringer Ingelheim Investigational Site
Louvigne De Bie, France
1218.74.33012 Boehringer Ingelheim Investigational Site
Maintenon, France
1218.74.33026 Boehringer Ingelheim Investigational Site
Orthez, France
1218.74.33019 Boehringer Ingelheim Investigational Site
Orthez, France
1218.74.33031 Boehringer Ingelheim Investigational Site
Palau Del Vidre, France
1218.74.33003 Boehringer Ingelheim Investigational Site
St Dié des Vosges Cedex, France
1218.74.33014 Boehringer Ingelheim Investigational Site
St Genies des Fontaines, France
1218.74.33009 Boehringer Ingelheim Investigational Site
Thouars, France
1218.74.33017 Boehringer Ingelheim Investigational Site
Tilly sur Seulles, France
Georgia
1218.74.99507 Boehringer Ingelheim Investigational Site
Batumi, Georgia
1218.74.99509 Boehringer Ingelheim Investigational Site
Gori, Georgia
1218.74.99508 Boehringer Ingelheim Investigational Site
Kutaisi, Georgia
1218.74.99501 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99502 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99503 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99504 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99506 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99505 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1218.74.99510 Boehringer Ingelheim Investigational Site
Zugdidi, Georgia
Germany
1218.74.49028 Boehringer Ingelheim Investigational Site
Aachen, Germany
1218.74.49020 Boehringer Ingelheim Investigational Site
Aschaffenburg, Germany
1218.74.49045 Boehringer Ingelheim Investigational Site
Asslar, Germany
1218.74.49008 Boehringer Ingelheim Investigational Site
Augsburg, Germany
1218.74.49001 Boehringer Ingelheim Investigational Site
Bad Nauheim, Germany
1218.74.49002 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.74.49003 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.74.49032 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.74.49035 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.74.49029 Boehringer Ingelheim Investigational Site
Dormagen- Hackenbroich, Germany
1218.74.49044 Boehringer Ingelheim Investigational Site
Dortmund, Germany
1218.74.49014 Boehringer Ingelheim Investigational Site
Dresden, Germany
1218.74.49038 Boehringer Ingelheim Investigational Site
Eisenach, Germany
1218.74.49012 Boehringer Ingelheim Investigational Site
Elsterwerda, Germany
1218.74.49019 Boehringer Ingelheim Investigational Site
Essen, Germany
1218.74.49039 Boehringer Ingelheim Investigational Site
Flörsheim, Germany
1218.74.49024 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
1218.74.49011 Boehringer Ingelheim Investigational Site
Furth im Wald, Germany
1218.74.49023 Boehringer Ingelheim Investigational Site
Gebhardshain, Germany
1218.74.49036 Boehringer Ingelheim Investigational Site
Haag, Germany
1218.74.49006 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1218.74.49030 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1218.74.49047 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1218.74.49034 Boehringer Ingelheim Investigational Site
Hamburg, Germany
1218.74.49015 Boehringer Ingelheim Investigational Site
Kirchhatten, Germany
1218.74.49022 Boehringer Ingelheim Investigational Site
Köln, Germany
1218.74.49021 Boehringer Ingelheim Investigational Site
Künzing, Germany
1218.74.49033 Boehringer Ingelheim Investigational Site
Leipzig, Germany
1218.74.49025 Boehringer Ingelheim Investigational Site
Lübeck, Germany
1218.74.49010 Boehringer Ingelheim Investigational Site
Mainz, Germany
1218.74.49048 Boehringer Ingelheim Investigational Site
Münster, Germany
1218.74.49004 Boehringer Ingelheim Investigational Site
Neumünster, Germany
1218.74.49017 Boehringer Ingelheim Investigational Site
Rehburg-Loccum, Germany
1218.74.49046 Boehringer Ingelheim Investigational Site
Rodgau/Dudenhofen, Germany
1218.74.49018 Boehringer Ingelheim Investigational Site
Saarbrücken, Germany
1218.74.49016 Boehringer Ingelheim Investigational Site
Schwabenheim, Germany
1218.74.49041 Boehringer Ingelheim Investigational Site
St. Ingbert / Oberwürzbach, Germany
1218.74.49037 Boehringer Ingelheim Investigational Site
Wangen, Germany
1218.74.49040 Boehringer Ingelheim Investigational Site
Zwenkau, Germany
Greece
1218.74.30008 Boehringer Ingelheim Investigational Site
Athens, Greece
1218.74.30006 Boehringer Ingelheim Investigational Site
Haidari, Athens, Greece
1218.74.30007 Boehringer Ingelheim Investigational Site
Ioannina, Greece
1218.74.30004 Boehringer Ingelheim Investigational Site
Melissia, Athens, Greece
1218.74.30009 Boehringer Ingelheim Investigational Site
Nikaia, Greece
1218.74.30005 Boehringer Ingelheim Investigational Site
Pylaia, Thessaloniki, Greece
1218.74.30001 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
1218.74.30002 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
1218.74.30010 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
Hong Kong
1218.74.85201 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1218.74.85202 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1218.74.85203 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
Hungary
1218.74.36008 Boehringer Ingelheim Investigational Site
Ajka, Hungary
1218.74.36005 Boehringer Ingelheim Investigational Site
Baja, Hungary
1218.74.36009 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.74.36001 Boehringer Ingelheim Investigational Site
Gyula, Hungary
1218.74.36006 Boehringer Ingelheim Investigational Site
Hódmezövásárhely, Hungary
1218.74.36002 Boehringer Ingelheim Investigational Site
Mako, Hungary
1218.74.36007 Boehringer Ingelheim Investigational Site
Mosonmagyarovar, Hungary
1218.74.36003 Boehringer Ingelheim Investigational Site
Papa, Hungary
1218.74.36004 Boehringer Ingelheim Investigational Site
Szekszard, Hungary
India
1218.74.91020 Boehringer Ingelheim Investigational Site
Ahmedabad, India
1218.74.91030 Boehringer Ingelheim Investigational Site
Aurangabad, India
1218.74.91003 Boehringer Ingelheim Investigational Site
Bangalore, India
1218.74.91004 Boehringer Ingelheim Investigational Site
Bangalore, India
1218.74.91007 Boehringer Ingelheim Investigational Site
Bangalore, India
1218.74.91009 Boehringer Ingelheim Investigational Site
Bangalore, Karnataka, India
1218.74.91027 Boehringer Ingelheim Investigational Site
Belgaum, India
1218.74.91023 Boehringer Ingelheim Investigational Site
Chennai, India
1218.74.91002 Boehringer Ingelheim Investigational Site
Chennai, India
1218.74.91018 Boehringer Ingelheim Investigational Site
Chennai, India
1218.74.91008 Boehringer Ingelheim Investigational Site
Chennai, India
1218.74.91025 Boehringer Ingelheim Investigational Site
Coimbatore, India
1218.74.91029 Boehringer Ingelheim Investigational Site
Indore, India
1218.74.91024 Boehringer Ingelheim Investigational Site
Jaipur, India
1218.74.91031 Boehringer Ingelheim Investigational Site
Jaipur, India
1218.74.91033 Boehringer Ingelheim Investigational Site
Maharashtra, India
1218.74.91032 Boehringer Ingelheim Investigational Site
Mumbai, India
1218.74.91006 Boehringer Ingelheim Investigational Site
Mumbai, India
1218.74.91028 Boehringer Ingelheim Investigational Site
Mumbai, Maharastra, India
1218.74.91021 Boehringer Ingelheim Investigational Site
Nagpur, India
1218.74.91001 Boehringer Ingelheim Investigational Site
Pune, India
1218.74.91014 Boehringer Ingelheim Investigational Site
Pune, India
1218.74.91026 Boehringer Ingelheim Investigational Site
Thiruvananthapuram, India
1218.74.91022 Boehringer Ingelheim Investigational Site
Vijayawada, India
Ireland
1218.74.35305 Boehringer Ingelheim Investigational Site
Co. Cork, Ireland
1218.74.35302 Boehringer Ingelheim Investigational Site
Dublin, Ireland
1218.74.35301 Boehringer Ingelheim Investigational Site
Gorey, Ireland
1218.74.35303 Boehringer Ingelheim Investigational Site
Wexford, Ireland
Israel
1218.74.97208 Boehringer Ingelheim Investigational Site
Ashkelon, Israel
1218.74.97205 Boehringer Ingelheim Investigational Site
Haifa, Israel
1218.74.97209 Boehringer Ingelheim Investigational Site
Holon, Israel
1218.74.97201 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
1218.74.97206 Boehringer Ingelheim Investigational Site
Nahariya, Israel
1218.74.97207 Boehringer Ingelheim Investigational Site
Tel Hashomer, Israel
1218.74.97203 Boehringer Ingelheim Investigational Site
Tel-Aviv, Israel
Italy
1218.74.39005 Boehringer Ingelheim Investigational Site
Cagliari, Italy
1218.74.39006 Boehringer Ingelheim Investigational Site
Catanzaro, Italy
1218.74.39013 Boehringer Ingelheim Investigational Site
Genova, Italy
1218.74.39008 Boehringer Ingelheim Investigational Site
Guastalla (RE), Italy
1218.74.39007 Boehringer Ingelheim Investigational Site
Messina, Italy
1218.74.39001 Boehringer Ingelheim Investigational Site
Milano, Italy
1218.74.39010 Boehringer Ingelheim Investigational Site
Roma, Italy
1218.74.39011 Boehringer Ingelheim Investigational Site
Roma, Italy
1218.74.39014 Boehringer Ingelheim Investigational Site
Sesto San Giovanni (MI), Italy
Japan
1218.74.81004 Boehringer Ingelheim Investigational Site
Amagasaki,Hyogo, Japan
1218.74.81010 Boehringer Ingelheim Investigational Site
Date, Fukushima, Japan
1218.74.81003 Boehringer Ingelheim Investigational Site
Hanyu,Saitama, Japan
1218.74.81014 Boehringer Ingelheim Investigational Site
Itabashi-ku,Tokyo, Japan
1218.74.81005 Boehringer Ingelheim Investigational Site
Kumamoto,Kumamoto, Japan
1218.74.81002 Boehringer Ingelheim Investigational Site
Matsudo,Chiba, Japan
1218.74.81006 Boehringer Ingelheim Investigational Site
Matsudo,Chiba, Japan
1218.74.81013 Boehringer Ingelheim Investigational Site
Miyazaki, Miyazaki, Japan
1218.74.81001 Boehringer Ingelheim Investigational Site
Nagoya,Aichi, Japan
1218.74.81011 Boehringer Ingelheim Investigational Site
Nihonmatsu, Fukushima, Japan
1218.74.81008 Boehringer Ingelheim Investigational Site
Sukagawa, Fukushima, Japan
1218.74.81007 Boehringer Ingelheim Investigational Site
Takasago,Hyogo, Japan
1218.74.81009 Boehringer Ingelheim Investigational Site
Yatsushiro, Kumamoto, Japan
1218.74.81012 Boehringer Ingelheim Investigational Site
Yokohama, Kanagawa, Japan
Korea, Republic of
1218.74.82012 Boehringer Ingelheim Investigational Site
Ansan, Korea, Republic of
1218.74.82003 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1218.74.82014 Boehringer Ingelheim Investigational Site
Daegu, Korea, Republic of
1218.74.82004 Boehringer Ingelheim Investigational Site
Goyang, Korea, Republic of
1218.74.82011 Boehringer Ingelheim Investigational Site
Goyang, Korea, Republic of
1218.74.82010 Boehringer Ingelheim Investigational Site
Goyang, Korea, Republic of
1218.74.82008 Boehringer Ingelheim Investigational Site
Jeonju, Korea, Republic of
1218.74.82015 Boehringer Ingelheim Investigational Site
Pusan, Korea, Republic of
1218.74.82009 Boehringer Ingelheim Investigational Site
Seongnam, Korea, Republic of
1218.74.82006 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.74.82007 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.74.82005 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.74.82001 Boehringer Ingelheim Investigational Site
Suwon, Korea, Republic of
1218.74.82013 Boehringer Ingelheim Investigational Site
Wonju, Korea, Republic of
1218.74.82002 Boehringer Ingelheim Investigational Site
Yangsan, Korea, Republic of
Malaysia
1218.74.60007 Boehringer Ingelheim Investigational Site
Johor Bahru, Johor, Malaysia
1218.74.60004 Boehringer Ingelheim Investigational Site
Kota Bharu, Malaysia
1218.74.60005 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1218.74.60002 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1218.74.60003 Boehringer Ingelheim Investigational Site
Kuantan, Malaysia
1218.74.60008 Boehringer Ingelheim Investigational Site
Melaka, Malaysia
1218.74.60006 Boehringer Ingelheim Investigational Site
Penang, Malaysia
1218.74.60001 Boehringer Ingelheim Investigational Site
Taiping, Malaysia
Mexico
1218.74.52006 Boehringer Ingelheim Investigational Site
Acapulco, Mexico
1218.74.52005 Boehringer Ingelheim Investigational Site
Aguascalientes, Mexico
1218.74.52004 Boehringer Ingelheim Investigational Site
Distrito Federal, Mexico
1218.74.52001 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
1218.74.52002 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1218.74.52003 Boehringer Ingelheim Investigational Site
Veracruz, Mexico
Netherlands
1218.74.31003 Boehringer Ingelheim Investigational Site
's-hertogenbosch, Netherlands
1218.74.31001 Boehringer Ingelheim Investigational Site
Almere, Netherlands
1218.74.31018 Boehringer Ingelheim Investigational Site
Amsterdam, Netherlands
1218.74.31009 Boehringer Ingelheim Investigational Site
Beverwijk, Netherlands
1218.74.31015 Boehringer Ingelheim Investigational Site
Breda, Netherlands
1218.74.31019 Boehringer Ingelheim Investigational Site
Den Helder, Netherlands
1218.74.31016 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
1218.74.31011 Boehringer Ingelheim Investigational Site
Groningen, Netherlands
1218.74.31006 Boehringer Ingelheim Investigational Site
Hoorn, Netherlands
1218.74.31023 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1218.74.31012 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1218.74.31020 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1218.74.31024 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1218.74.31010 Boehringer Ingelheim Investigational Site
Sneek, Netherlands
1218.74.31017 Boehringer Ingelheim Investigational Site
Velp, Netherlands
1218.74.31013 Boehringer Ingelheim Investigational Site
Zoetermeer, Netherlands
1218.74.31014 Boehringer Ingelheim Investigational Site
Zoetermeer, Netherlands
New Zealand
1218.74.64005 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand
1218.74.64004 Boehringer Ingelheim Investigational Site
Dunedin, New Zealand
1218.74.64001 Boehringer Ingelheim Investigational Site
Newtown Wellington NZ, New Zealand
1218.74.64002 Boehringer Ingelheim Investigational Site
Tauranga, New Zealand
Norway
1218.74.47008 Boehringer Ingelheim Investigational Site
Bodø, Norway
1218.74.47009 Boehringer Ingelheim Investigational Site
Drammen, Norway
1218.74.47004 Boehringer Ingelheim Investigational Site
Elverum, Norway
1218.74.47003 Boehringer Ingelheim Investigational Site
Hamar, Norway
1218.74.47011 Boehringer Ingelheim Investigational Site
Jessheim, Norway
1218.74.47012 Boehringer Ingelheim Investigational Site
Lierskogen, Norway
1218.74.47010 Boehringer Ingelheim Investigational Site
Oslo, Norway
1218.74.47002 Boehringer Ingelheim Investigational Site
Sandvika, Norway
1218.74.47006 Boehringer Ingelheim Investigational Site
Sarpsborg, Norway
1218.74.47013 Boehringer Ingelheim Investigational Site
Stavanger, Norway
1218.74.47005 Boehringer Ingelheim Investigational Site
Ålesund, Norway
Peru
1218.74.51004 Boehringer Ingelheim Investigational Site
Arequipa, Peru
1218.74.51007 Avenida Echenique 641
Huacho, Peru
1218.74.51001 Boehringer Ingelheim Investigational Site
Lima, Peru
1218.74.51002 Boehringer Ingelheim Investigational Site
Lima, Peru
1218.74.51005 Boehringer Ingelheim Investigational Site
Lima, Peru
1218.74.51009 Calle Manuel Raygada #170
Lima, Peru
1218.74.51011 Avenida La Marina 2955 oficina 311
Lima, Peru
1218.74.51008 Boehringer Ingelheim Investigational Site
Piura, Peru
Philippines
1218.74.63005 Boehringer Ingelheim Investigational Site
Iloilo, Philippines
1218.74.63010 Boehringer Ingelheim Investigational Site
Lipa City, Batangas, Philippines
1218.74.63002 Boehringer Ingelheim Investigational Site
Manila, Philippines
1218.74.63006 Boehringer Ingelheim Investigational Site
Manila, Philippines
1218.74.63011 Boehringer Ingelheim Investigational Site
Manila, Philippines
1218.74.63007 Boehringer Ingelheim Investigational Site
Muntinlupa, Philippines
1218.74.63008 Boehringer Ingelheim Investigational Site
Quezon City, Philippines
1218.74.63009 Boehringer Ingelheim Investigational Site
Quezon City, Philippines
1218.74.63001 Boehringer Ingelheim Investigational Site
San Juan, Philippines
1218.74.63003 Boehringer Ingelheim Investigational Site
Surigao, Philippines
Portugal
1218.74.35101 Boehringer Ingelheim Investigational Site
Amadora, Portugal
1218.74.35105 Boehringer Ingelheim Investigational Site
Carnaxide, Portugal
1218.74.35104 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1218.74.35102 Boehringer Ingelheim Investigational Site
Covilhã, Portugal
1218.74.35103 Boehringer Ingelheim Investigational Site
Figueira da Foz, Portugal
1218.74.35109 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1218.74.35107 Boehringer Ingelheim Investigational Site
Porto, Portugal
1218.74.35106 Boehringer Ingelheim Investigational Site
Santa Maria da Feira, Portugal
Romania
1218.74.40005 Boehringer Ingelheim Investigational Site
Brasov, Romania
1218.74.40002 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1218.74.40003 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1218.74.40001 Boehringer Ingelheim Investigational Site
Iasi, Romania
1218.74.40006 Boehringer Ingelheim Investigational Site
Sibiu, Romania
1218.74.40004 Boehringer Ingelheim Investigational Site
Tirgoviste, Romania
Russian Federation
1218.74.70009 Boehringer Ingelheim Investigational Site
Dzerzhinsky, Russian Federation
1218.74.70007 Boehringer Ingelheim Investigational Site
Izhevsk, Russian Federation
1218.74.70001 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.74.70002 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.74.70004 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.74.70005 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.74.70008 Boehringer Ingelheim Investigational Site
Rostov-na-Donu, Russian Federation
1218.74.70003 Boehringer Ingelheim Investigational Site
Samara, Russian Federation
1218.74.70006 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
Serbia
1218.74.38103 Boehringer Ingelheim Investigational Site
Belgrade, Serbia
1218.74.38101 Boehringer Ingelheim Investigational Site
Nis, Serbia
1218.74.38106 Boehringer Ingelheim Investigational Site
Pancevo, Serbia
1218.74.38104 Boehringer Ingelheim Investigational Site
Subotica, Serbia
1218.74.38102 Boehringer Ingelheim Investigational Site
Zemun, Serbia
Slovakia
1218.74.42108 Boehringer Ingelheim Investigational Site
Banska Bystrica, Slovakia
1218.74.42106 Boehringer Ingelheim Investigational Site
Dolny Kubin, Slovakia
1218.74.42101 Boehringer Ingelheim Investigational Site
Levice, Slovakia
1218.74.42102 Boehringer Ingelheim Investigational Site
Levice, Slovakia
1218.74.42103 Boehringer Ingelheim Investigational Site
Nove Zamky, Slovakia
1218.74.42107 Boehringer Ingelheim Investigational Site
Povazska Bystrica, Slovakia
1218.74.42105 Boehringer Ingelheim Investigational Site
Zilina, Slovakia
South Africa
1218.74.27006 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.74.27008 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.74.27002 Boehringer Ingelheim Investigational Site
Durban, South Africa
1218.74.27005 Boehringer Ingelheim Investigational Site
Durban, South Africa
1218.74.27007 Boehringer Ingelheim Investigational Site
Krugersdorp, South Africa
1218.74.27003 Boehringer Ingelheim Investigational Site
Lenasia, South Africa
1218.74.27004 Boehringer Ingelheim Investigational Site
Lenasia, South Africa
1218.74.27011 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
1218.74.27013 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.74.27001 Boehringer Ingelheim Investigational Site
Somerset West, South Africa
Spain
1218.74.34002 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.74.34001 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.74.34003 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.74.34012 Boehringer Ingelheim Investigational Site
Burjassot, Spain
1218.74.34020 Boehringer Ingelheim Investigational Site
Gijon, Spain
1218.74.34005 Boehringer Ingelheim Investigational Site
Girona, Spain
1218.74.34004 Boehringer Ingelheim Investigational Site
L'Hospitalet de Llobregat, Spain
1218.74.34021 Boehringer Ingelheim Investigational Site
L'Hospitalet de Llobregat, Spain
1218.74.34006 Boehringer Ingelheim Investigational Site
La Roca del Vallés (Barcelona), Spain
1218.74.34013 Boehringer Ingelheim Investigational Site
Madrid, Spain
1218.74.34015 Boehringer Ingelheim Investigational Site
Oviedo, Spain
1218.74.34016 Boehringer Ingelheim Investigational Site
Oviedo, Spain
1218.74.34018 Boehringer Ingelheim Investigational Site
Oviedo, Spain
1218.74.34008 Boehringer Ingelheim Investigational Site
Pineda de Mar, Spain
1218.74.34007 Boehringer Ingelheim Investigational Site
Santa Coloma de Gramanet, Spain
1218.74.34009 Boehringer Ingelheim Investigational Site
Tàrrega, Spain
1218.74.34010 Boehringer Ingelheim Investigational Site
Valencia, Spain
1218.74.34011 Boehringer Ingelheim Investigational Site
Valencia, Spain
Sweden
1218.74.46005 Boehringer Ingelheim Investigational Site
Göteborg, Sweden
1218.74.46010 Boehringer Ingelheim Investigational Site
Härnösand, Sweden
1218.74.46003 Boehringer Ingelheim Investigational Site
Järfälla, Sweden
1218.74.46001 Boehringer Ingelheim Investigational Site
Malmö, Sweden
1218.74.46008 Boehringer Ingelheim Investigational Site
Rättvik, Sweden
1218.74.46011 Boehringer Ingelheim Investigational Site
Rättvik, Sweden
1218.74.46007 Boehringer Ingelheim Investigational Site
Skanör, Sweden
1218.74.46002 Boehringer Ingelheim Investigational Site
Uddevalla, Sweden
1218.74.46009 Boehringer Ingelheim Investigational Site
Vällingby, Sweden
Switzerland
1218.74.41009 Boehringer Ingelheim Investigational Site
Basel, Switzerland
1218.74.41001 Boehringer Ingelheim Investigational Site
Bellinzona, Switzerland
1218.74.41004 Boehringer Ingelheim Investigational Site
Bern, Switzerland
1218.74.41003 Boehringer Ingelheim Investigational Site
Lugano, Switzerland
Taiwan
1218.74.88609 Changhua Christian Hospital
Changhua, Taiwan
1218.74.88610 E-Da Hospital
Kaohsiung, Taiwan
1218.74.88611 Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
1218.74.88605 Far Eastern Memorial Hospital
New Taipei City, Taiwan
1218.74.88607 China Medical University Hospital
Taichung, Taiwan
1218.74.88608 Taichung Veterans General Hospital
Taichung,, Taiwan
1218.74.88612 National Cheng Kung University Hospital
Tainan, Taiwan
1218.74.88601 National Taiwan University Hospital
Taipei, Taiwan
1218.74.88602 Shih-Kong Wu Ho-Shu Memorial Hospital
Taipei, Taiwan
1218.74.88603 Tri-Service General Hospital
Taipei, Taiwan
1218.74.88604 Cardinal Tien Hospital
Taipei, Taiwan
1218.74.88606 Taipei Veterans General Hospital
Taipei, Taiwan
1218.74.88613 Taipei Medical University-Shuang Ho Hospital
Taipei, Taiwan
1218.74.88614 Cheng Hsin Gneral Hospital
Taipei, Taiwan
1218.74.88615 Mackay Memorial Hospital
Taipei, Taiwan
Tunisia
1218.74.2161 Boehringer Ingelheim Investigational Site
Monastir, Tunisia
1218.74.2164 Boehringer Ingelheim Investigational Site
Sfax, Tunisia
1218.74.2162 Boehringer Ingelheim Investigational Site
Sousse, Tunisia
1218.74.2163 Boehringer Ingelheim Investigational Site
Tunis, Tunisia
Ukraine
1218.74.38004 Boehringer Ingelheim Investigational Site
Donetsk, Ukraine
1218.74.38008 Boehringer Ingelheim Investigational Site
Ivano-Frankivsk, Ukraine
1218.74.38005 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1218.74.38010 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
1218.74.38006 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1218.74.38009 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1218.74.38001 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.74.38007 Boehringer Ingelheim Investigational Site
Lvov, Ukraine
1218.74.38003 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
1218.74.38002 Boehringer Ingelheim Investigational Site
Vinnitsa, Ukraine
United Kingdom
1218.74.44006 Boehringer Ingelheim Investigational Site
Addlestone, United Kingdom
1218.74.44028 Boehringer Ingelheim Investigational Site
Ash Vale, Aldershot, United Kingdom
1218.74.44010 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
1218.74.44022 Boehringer Ingelheim Investigational Site
Chippenham, United Kingdom
1218.74.44040 Boehringer Ingelheim Investigational Site
Durham, United Kingdom
1218.74.44030 Boehringer Ingelheim Investigational Site
Ely, United Kingdom
1218.74.44038 Boehringer Ingelheim Investigational Site
Gloucester, United Kingdom
1218.74.44039 Boehringer Ingelheim Investigational Site
Great Yarmouth, United Kingdom
1218.74.44041 Boehringer Ingelheim Investigational Site
London, United Kingdom
1218.74.44042 Boehringer Ingelheim Investigational Site
Swansea, United Kingdom
1218.74.44037 Boehringer Ingelheim Investigational Site
Truro, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01243424     History of Changes
Other Study ID Numbers: 1218.74, 2009-013157-15
Study First Received: November 17, 2010
Last Updated: November 5, 2014
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Australia: Dept of Health and Ageing Therapeutic Goods Admin
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Chile: Comision Nacional De Investigacion Cientifica y Tecnologica
Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Czech Republic: State Institute for Drug Control
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Georgia: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Greece: Ethics Committee
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Ireland: Irish Medicines Board
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ethics Committee
Japan: Ministry of Health, Labor and Welfare
Malaysia: Ministry of Health
Mexico: Federal Commission for Protection Against Health Risks
Netherlands: Central Committee Research Involving Human Subjects
New Zealand: Medsafe
Norway: Norwegian Medicines Agency
Peru: General Directorate of Pharmaceuticals, Devices, and Drugs
Philippines: Bureau of Food and Drugs
Portugal: National Pharmacy and Medicines Institute
Romania: Ministry of Public Health
Russia: Pharmacological Committee, Ministry of Health
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
Slovakia: State Institute for Drug Control
South Africa: Medicines Control Council
South Korea: Ministry of Food and Drug Safety (MFDS)
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Switzerland: Swissmedic
Taiwan : Food and Drug Administration
Tunisia: Ministry of Public Health
Tunisia:
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Glimepiride
Linagliptin
Anti-Arrhythmia Agents
Cardiovascular Agents
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Immunologic Factors
Immunosuppressive Agents
Incretins
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014